| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SR1001 | CTRPv2 | pan-cancer | AAC | -0.008 | 0.8 |
| mRNA | BRD-M00053801 | CTRPv2 | pan-cancer | AAC | -0.0097 | 0.8 |
| mRNA | docetaxel:tanespimycin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0066 | 0.8 |
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | 0.0073 | 0.8 |
| mRNA | BRD9647 | CTRPv2 | pan-cancer | AAC | -0.0075 | 0.8 |
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.8 |
| mRNA | GMX-1778 | CTRPv2 | pan-cancer | AAC | -0.0069 | 0.8 |
| mRNA | BRD-K48334597 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | 0.014 | 0.9 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.9 |